Epalex
Mountain View, US · Delaware corporation
Epalex is a clinical-stage pharmaceutical company developing therapies for migraine and epilepsy, focused on patients who are inadequately treated by or resistant to existing drugs. Its pipeline includes EP102 for hard-to-treat migraine and EP103, a non-benzodiazepine antiseizure agent for drug-refractory epilepsy, using a proprietary delivery technology.
Founders & leadership
BM
Brendan MagrabExecutive
EJ
Enrique J CarrazanaNamed on SEC filing
AF
Arthur Franklin RiceNamed on SEC filing
MS
Matthew SmithNamed on SEC filing
Board
DC
Didric CederholmBoard director
RM
Randall MurphyBoard director
JS
Jon S. SaxeBoard director
MR
Michael RogawskiBoard director
Reported raises · per SEC filings
Form D private placements$30.8M disclosed across 5 rounds · 2017–2025
▶$1.2MraisedNov 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedNov 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon SaxeDirector
- Brendan MagrabExecutive Officer, Director
- Randall MurphyDirector
- Didric CedarholmDirector
- Michael RogawskiDirector
- Offering amount
- $3.2M
- Amount sold
- $1.2M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedDec 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedDec 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon S. SaxeDirector
- Michael RogawskiDirector
- Brendan MagrabExecutive Officer, Director
- Didric CederholmDirector
- Randall MurphyDirector
- Offering amount
- $15M
- Amount sold
- $4M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedOct 2022 · 15 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedOct 2022 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew SmithDirector
- Michael RogawskiDirector
- Brendan MagrabExecutive Officer, Director
- Jon S. SaxeDirector
- Randall MurphyDirector
- Offering amount
- $8.5M
- Amount sold
- $4.3M
- Proceeds to insiders
- $650K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.3MraisedDec 2020 · 7 investors · PharmaceuticalsRule 506(b)
▶$20.3MraisedDec 2020 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brendan MagrabExecutive Officer, Director
- Jon S. SaxeDirector
- Randall MurphyDirector
- Matthew SmithDirector
- Michael RogawskiDirector
- Offering amount
- $20.3M
- Amount sold
- $20.3M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$999.3KraisedNov 2018 · 5 investors · PharmaceuticalsRule 506(b)
▶$999.3KraisedNov 2018 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Enrique J CarrazanaDirector
- Randall B MurphyDirector
- Arthur Franklin RiceExecutive Officer, Director
- Matthew SmithDirector
- Jon S SaxeDirector
- Michael RogawskiDirector
- Offering amount
- $1M
- Amount sold
- $999.3K
- Minimum investment
- $25K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Epalex do?
- Epalex is a clinical-stage pharmaceutical company developing therapies for migraine and epilepsy, focused on patients who are inadequately treated by or resistant to existing drugs. Its pipeline includes EP102 for hard-to-treat migraine and EP103, a non-benzodiazepine antiseizure agent for drug-refractory epilepsy, using a proprietary delivery technology.
- How much funding has Epalex raised?
- Epalex has disclosed $30.8M raised across 5 rounds.
- Where is Epalex headquartered?
- Epalex is headquartered in Mountain View, US.